This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
This page refreshes automatically every 30 mins. Press F5 to update manually
For a more detailed explanation of Upgrades/Downgrades see Link
Key: (?) = Upgraded, (?) = Downgraded, (-) = Maintained
| Stock | Broker Update |
| Astrazeneca | Barclays ups TP to 3800p from 3300p, Equalweight |
| Centrica | Credit Suisse ups to neutral from underperform |
| Electrocomponents | UBS removes from Most Preferred list, Buy |
| G4S | UBS adds to Most Preferred list, neutral |
| Glaxosmithkline | Barclays ups TP to 1780p from 1575p, Equalweight |
| Hikma Pharmaceuticals | Citigroup ups TP to 1700p from 1260p, Buy |
| Hunting | Canaccord Genuity ups TP to 950p from 900p, Buy |
| Japan Residential Investment | Jefferies initiates with Buy rating |
| Rolls-Royce | Liberum cuts TP to 1225p from 1300p , Buy |
| Shire | Barclays ups TP to 3600p from 3275p, overweight |
| Shire | Leerink ups TP to $190 from $170, outperform |
| Taylor Wimpey | Numis downgrades to Hold from add |
| Whitbread | Jefferies ups TP to 3900p from 3600p, Hold |
| Source: Reuters News, AlphaTerminal, Dow Jones Newswires | |
Source: Bloomberg, Reuters News, AlphaTerminal, Dow Jones Newswires
T111his research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research